Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Solid Tumor
Interventions: BIOLOGICAL: Pembrolizumab|COMBINATION_PRODUCT: MK-0482 + Pembrolizumab|COMBINATION_PRODUCT: MK-4830 + Pembrolizumab
Sponsor: Presage Biosciences
Collaborators: Merck Sharp & Dohme LLC